Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer

Welcome back to another Pharmacy Times Peer Exchange series. In this episode, “Navigating the Clinical and Economic Burden of Endometrial Cancer,” Megan May, PharmD, BCOP, FHOPA, FAPO, leads the conversation about the following question:

Describe the clinical and economic burden that endometrial cancer places on patients and the health care system in general.

The panelists highlighted the rising incidence of endometrial cancer and the increasing prevalence of aggressive histologic subtypes, such as serous and carcinosarcoma. The experts noted that Black women are disproportionately affected by the disease and are more likely to face higher mortality rates. The discussion also emphasized the critical importance of clinical trial enrollment and early screening for abnormal uterine bleeding to improve outcomes in higher-stage presentations.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, “Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer,” panelists continue their discussion on endometrial cancer and highlight the importance of overall survival (OS) as a gold-standard end point and how maturing trial data influences clinical decision-making.